In 2020, the FDA rejected Intercept’s medicine and requested completion of a Pha...
Pfizer is set to discontinue one of its oral obesity drugs – namely lotiglipron ...
Pfizer’s Talzenna has received FDA approval as a second PARP inhibitor for prost...
A recent Phase 2 study conducted by Union Therapeutics has yielded positive resu...
The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disea...
Despite being best recognized for its biosimilars business, Coherus has been try...
The Food and Drug Administration (FDA) in the U.S. has rejected the U.K.-based F...
Colchicine was first used as a treatment for inflammation in Egypt more than 350...
AstraZeneca’s decision to abandon its remaining clinical candidate, AZD0186, mar...
AstraZeneca is partnering up with a self-identified “young” Chinese company to c...
Aldeyra Therapeutics has just shared results for its phase 3 trial, the INVIGORA...
AbbVie’s Skyrizi has posted another victory in a maintenance trial after complet...
An additional FDA hold has been placed on Mersana Therapeutics in connection wit...
Novartis, the Swiss pharmaceutical giant, is set to bolster its kidney disease p...
AstraZeneca has entered the field of autoimmune cell therapy by partnering with ...
Cue Health has received the FDA’s first approval for regular use of a COVID-19 a...
